NAMPT/IDO1-IN-1 is an orally active dual inhibitor targeting NAMPT and IDO1 (IC50 = 57.5 nM and 233 nM, respectively); it blocks NAD+ biosynthesis, inhibits proliferation and migration of paclitaxel- and FK866-resistant NSCLC A549/R cells, exhibits antitumor activity in mice, and enhances the sensitivity of A549/R cells to paclitaxel.